ClinicalTrials.gg
TerminatedNCT01436175Updated Jun 14, 2021Results posted

SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study

A Phase 3 interventional study of SPD489 (Lisdexamfetamine dimesylate) + Antidepressant in Major Depressive Disorder, sponsored by Shire. Terminated at 212 sites in 14 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Why this study was terminated
SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,570
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Depressive Disorder, Major by Takeda — 1 open to participants now, 1 under way, 1 of them phase 3. Depressive Disorder, Major · Takeda.

Enrollment
Largest of 24
1,570 · median 580
Started
2012
with 1 other
Phase 3
16 of 26
1 open now
Registered
15th of 26
by date

Among the 26 studies in Depressive Disorder, Major by Takeda, this one has the largest enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2012, is one of 16 in phase 3, and was the 15th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 26 studies in Depressive Disorder, Major by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Depressive Disorder, Major by Takeda, or all of them as a file.
02

Study summary

This study is an optional continuation of previous short-term adult major depressive disorder (MDD) augmentation studies. Patients may only take part in this long-term, open-label research study if they completed a previous double-blind MDD augmentation study using SPD489.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has completed 1 of the respective short-term antecedent SPD489 MDD studies and did not experience any AEs in the antecedent study that would preclude exposure to SPD489.

Exclusion criteria

Exclusion Criteria:

  • Subject has any current co-morbid Axis I or Axis II psychiatric disorder (including a lifetime history of psychosis) which was not present or recognized at entry into the antecedent study or has a concurrent chronic or acute illness or unstable medical condition that may deteriorate that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,570 participants (actual)

Study arms

  • Experimental
    SPD489 + Antidepressant

    Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant

Interventions

  • DrugSPD489 (Lisdexamfetamine dimesylate) + Antidepressant

    Drug page: Lisdexamfetamine

    SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks

    Also known as: Vyvanse, LDX

06

What researchers measure

Primary outcomes

  1. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviour during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

    Time frame: Week 5 up to Week 52/Early Termination(ET)

  2. Change From Baseline in Systolic Blood Pressure at Week 52

    Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

    Time frame: Baseline, Week 52/ET

  3. Change From Baseline in Diastolic Blood Pressure at Week 52

    Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

    Time frame: Baseline, Week 52/ET

  4. Change From Baseline in Pulse Rate at Week 52

    Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

    Time frame: Baseline, Week 52/ET

Secondary outcomes

  1. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET

    Designed to evaluate the extent to which illness symptoms impact a participant's life in 3 areas: work, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

    Time frame: Baseline, Week 52/ET

  2. Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)

    Participants who did not have Clinical Global Impressions - Severity of Illness (CGI-S) assessed at Week 8 in the antecedent study should not have had CGI-I assessed in this study and were excluded from the summary of CGI-I. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Week 52/ET

  3. Short Form-12 Health Survey Version 2 (SF-12V2)

    SF-12V2 is a multi-purpose, 7-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It is expressed by two summary measures (Aggregate Physical and Aggregate Mental) for which values can range from 0 to 100. A higher score is indicative of a better health state.

    Time frame: Week 52/ET

  4. EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

    Time frame: Week 52/ET

  5. EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

    Time frame: Week 52/ET

  6. EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

    Time frame: Week 52/ET

  7. EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

    Time frame: Week 52/ET

  8. EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression

    Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

    Time frame: Week 52/ET

  9. EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale

    EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. EQ-5D-5L Visual Analog Scale score is numbered from 0 to 100, where a score of 100 is the best health a participant can imagine

    Time frame: Week 52/ET

  10. Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)

    QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. The QIDS-SR was only assessed in the SPD489-322 antecedent study. The QIDS-SR total score is calculated as the sum of the highest score on any 1 of Items 1-4, Item 5, the highest score on any 1 of Items 6-9, Items 10-14, the highest score on either Item 15 or 16.

    Time frame: Week 52/ET

  11. Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)

    The Q-LES-Q-SF is a 16-item self-report questionnaire which evaluates general participant satisfaction with health, mood, relationships, functioning in daily life, and their treatment. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total raw score (summary scale score) was calculated by summing item scores 1 to 14 (total raw score range: 14 to 70). Item 15 (satisfaction with medication, raw score range: 1 to 5) and Item 16 (overall satisfaction and contentment; raw score range: 1 to 5) were stand-alone items. For reporting, summary scale, Item 15 and Item 16 raw scores were transformed into percentage maximum possible score which ranged from 0 to 100, where higher scores are indicative of greater enjoyment or satisfaction.

    Time frame: Week 52/ET

  12. Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET

    CSFQ-14 is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

    Time frame: Baseline, Week 52/ET

  13. Amphetamine Cessation Symptom Assessment (ACSA) Total Score

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: Week 53

  14. Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)

    The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered the following questions: 1. Were you hospitalized in the past month, 2. Do you work for pay, 3. If you missed time at work last week, please note all the reasons why, 4. Would you say that the past week was typical, like the rest of the 3 weeks this month, in terms of your working hours, 5. Do you do volunteer work (VW), and 6. If you do not receive money for your work and do not participate in volunteer work, the reason is. Number of participants with response is reported.

    Time frame: Week 52/ET

  15. PRUQ-MDD - Number of Days of Resource Utilization

    The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Number of nights in medical/surgical ward, number of nights in ICU, and number of days a participant received home care in the past month are reported.

    Time frame: Week 52/ET

  16. PRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)

    The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many times did you visit the following healthcare providers in the past month: Family doctor/primary care, Non-physician healthcare practitioner (NPHP), Psychiatrist/Psychologist/Counselor (PPC); 2. How many times did you take one of the tests, mentioned below, during the past month: Blood test, CT Scan, X Ray, Renal function, Thyroid function; and 3. How many times did you visit the hospital emergency room (ER), urgent care facility (UCF) or an after-hours clinic (AHC) in the past month. Number of events (visit to health care provider, visit to hospital facilities, and number of times a test was performed) are reported.

    Time frame: Week 52/ET

  17. PRUQ-MDD - Number of Hours

    The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many hours do you usually work or would you usually be expected to work (hrs/week); 2. How many hours did you actually work last week; 3. On average, how many hours do you volunteer per week. Number of hours are reported.

    Time frame: Week 52/ET

  18. PRUQ-MDD - Effect of Depressive Symptoms

    The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions on a 0 to 10 point scale - 1. During past week, how much did depressive symptoms affect work productivity; 2. During past week, how much did depressive symptoms affect regular non-work daily activities. Higher scores indicates more effect of depressive symptoms on work productivity and non-work daily activities.

    Time frame: Week 52/ET

07

Results

Posted Feb 23, 2015
Limitations and caveats
The study was terminated on 11 Feb 2014. SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.

Participant flow

Study enrolled eligible adults with major depressive disorder (MDD) who had completed treatment in a short-term antecedent SPD489 (lisdexamfetamine dimesylate) MDD study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Participant flow — Overall Study
MilestoneSPD489 + Antidepressant
Started1570
Completed300
Not completed1270
Withdrew: Adverse event111
Withdrew: Protocol violation49
Withdrew: Withdrawal by subject108
Withdrew: Lost to follow-up89
Withdrew: Lack of efficacy24
Withdrew: Met blood pressure or pulse withdrawal63
Withdrew: Other826

Outcome measures

PrimaryColumbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviour during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.

Time frame:
Week 5 up to Week 52/Early Termination(ET)
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsSPD489 + Antidepressant
Positive Suicidal Ideation68
Suicidal Attempt4
PrimaryChange From Baseline in Systolic Blood Pressure at Week 52

Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Time frame:
Baseline, Week 52/ET
Reported as:
Mean · millimeter of mercury(mmHg)
Change From Baseline in Systolic Blood Pressure at Week 52
millimeter of mercury(mmHg)SPD489 + Antidepressant
Baseline (n = 1559)117.6 ± 11.13
Change at Week 52/ET (n = 1558)2.4 ± 10.37
PrimaryChange From Baseline in Diastolic Blood Pressure at Week 52

Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Time frame:
Baseline, Week 52/ET
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure at Week 52
mmHgSPD489 + Antidepressant
Baseline (n = 1559)75.4 ± 8.15
Change at Week 52/ET (n = 1558)1.2 ± 7.94
PrimaryChange From Baseline in Pulse Rate at Week 52

Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Time frame:
Baseline, Week 52/ET
Reported as:
Mean · beats per minute(bpm)
Change From Baseline in Pulse Rate at Week 52
beats per minute(bpm)SPD489 + Antidepressant
Baseline (n = 1559)72.7 ± 9.90
Change at Week 52/ET (n = 1558)5.2 ± 10.58
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET

Designed to evaluate the extent to which illness symptoms impact a participant's life in 3 areas: work, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Time frame:
Baseline, Week 52/ET
Reported as:
Mean · units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 52/ET
units on a scaleSPD489 + Antidepressant
Baseline (n=1548)12.7 ± 7.06
Change at Week 52/ET (n = 1530)-4.3 ± 7.77
SecondaryNumber of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)

Participants who did not have Clinical Global Impressions - Severity of Illness (CGI-S) assessed at Week 8 in the antecedent study should not have had CGI-I assessed in this study and were excluded from the summary of CGI-I. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Week 52/ET
Reported as:
Number · participants
Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)
participantsSPD489 + Antidepressant
Number of Participants With Improvement on Clinical Global Impressions - Global Improvement (CGI-I)1021
SecondaryShort Form-12 Health Survey Version 2 (SF-12V2)

SF-12V2 is a multi-purpose, 7-item survey that measures 8 domains of health: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. It is expressed by two summary measures (Aggregate Physical and Aggregate Mental) for which values can range from 0 to 100. A higher score is indicative of a better health state.

Time frame:
Week 52/ET
Reported as:
Mean · units on a scale
Short Form-12 Health Survey Version 2 (SF-12V2)
units on a scaleSPD489 + Antidepressant
Aggregate Physical49.1 ± 9.67
Aggregate Mental42.7 ± 11.55
SecondaryEuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

Time frame:
Week 52/ET
Reported as:
Number · participants
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Mobility
participantsSPD489 + Antidepressant
No problems in walking about1193
Slight problems in walking about237
Moderate problems in walking about82
Severe problems in walking about24
Unable to walk about1
SecondaryEuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

Time frame:
Week 52/ET
Reported as:
Number · participants
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Self-Care
participantsSPD489 + Antidepressant
No problems washing or dressing myself1304
Slight problems washing or dressing myself174
Moderate problems washing or dressing myself49
Severe problems washing or dressing myself9
Unable to wash or dress myself1
SecondaryEuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

Time frame:
Week 52/ET
Reported as:
Number · participants
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Usual Activities
participantsSPD489 + Antidepressant
No problems doing my usual activities800
Slight problems doing my usual activities475
Moderate problems doing my usual activities197
Severe problems doing my usual activities55
Unable to do my usual activities10
SecondaryEuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

Time frame:
Week 52/ET
Reported as:
Number · participants
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Pain/Discomfort
participantsSPD489 + Antidepressant
No pain or discomfort715
Slight pain or discomfort536
Moderate pain or discomfort208
Severe pain or discomfort68
Extreme pain or discomfort10
SecondaryEuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression

Quality of life was assessed using the EQ-5D-5L, which is one of the most widely used generic index measures of health-related quality of life. It consists of a 5-item descriptive system that measures 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is represented by a single item with 5 levels of responses

Time frame:
Week 52/ET
Reported as:
Number · participants
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Anxiety/Depression
participantsSPD489 + Antidepressant
Not anxious or depressed461
Slightly anxious or depressed687
Moderately anxious or depressed289
Severely anxious or depressed73
Extremely anxious or depressed27
SecondaryEuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale

EQ-5D-5L is one of the most widely used generic index measures of health-related quality of life. EQ-5D-5L Visual Analog Scale score is numbered from 0 to 100, where a score of 100 is the best health a participant can imagine

Time frame:
Week 52/ET
Reported as:
Mean · units on a scale
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale
units on a scaleSPD489 + Antidepressant
EuroQoL Group 5-Dimension 5-Level Self Report Questionnaire (EQ-5D-5L): Visual Analog Scale75.7 ± 18.35
SecondaryQuick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)

QIDS-SR is a validated, self-reported rating scale that contains 16 items scored on a scale from 0-3 with total scores ranging from 0 (no depression) to 27 (very severe depression). Lower scores indicate less depression. The QIDS-SR was only assessed in the SPD489-322 antecedent study. The QIDS-SR total score is calculated as the sum of the highest score on any 1 of Items 1-4, Item 5, the highest score on any 1 of Items 6-9, Items 10-14, the highest score on either Item 15 or 16.

Time frame:
Week 52/ET
Reported as:
Mean · units on a scale
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)
units on a scaleSPD489 + Antidepressant
Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR)6.9 ± 4.48
SecondaryQuality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)

The Q-LES-Q-SF is a 16-item self-report questionnaire which evaluates general participant satisfaction with health, mood, relationships, functioning in daily life, and their treatment. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total raw score (summary scale score) was calculated by summing item scores 1 to 14 (total raw score range: 14 to 70). Item 15 (satisfaction with medication, raw score range: 1 to 5) and Item 16 (overall satisfaction and contentment; raw score range: 1 to 5) were stand-alone items. For reporting, summary scale, Item 15 and Item 16 raw scores were transformed into percentage maximum possible score which ranged from 0 to 100, where higher scores are indicative of greater enjoyment or satisfaction.

Time frame:
Week 52/ET
Reported as:
Mean · units on a scale
Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)
units on a scaleSPD489 + Antidepressant
Summary Scale (n = 506)61.5 ± 17.22
Satisfaction with Medication (n = 478)68.6 ± 19.66
Overall Satisfaction and Contentment (n = 506)63.2 ± 21.58
SecondaryChange From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET

CSFQ-14 is a 14 item self-report tool that evaluates sexual functioning. Each item is scored on a 5-point Likert scale ranging from 1 (never) to 5 (always) with total scores ranging from 14 to 70. Higher scores reflect better sexual functioning. Baseline was defined as the Augmentation Baseline Visit of the antecedent study (SPD489-209 \[NCT01435759\], SPD489-322 \[NCT01436149\], and SPD489-323 \[NCT01436162\]).

Time frame:
Baseline, Week 52/ET
Reported as:
Mean · units on a scale
Change From Baseline in Sexual Functioning Questionnaire - 14 Item Scale (CSFQ-14) Total Score at Week 52/ET
units on a scaleSPD489 + Antidepressant
Male: Baseline (n=167)46.6 ± 9.17
Male: Change at Week 52/ET (n=164)1.7 ± 7.16
Female: Baseline (n=341)37.2 ± 9.65
Female: Change at Week 52/ET (n=330)2.8 ± 8.33
SecondaryAmphetamine Cessation Symptom Assessment (ACSA) Total Score

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
Week 53
Reported as:
Mean · units on a scale
Amphetamine Cessation Symptom Assessment (ACSA) Total Score
units on a scaleSPD489 + Antidepressant
Amphetamine Cessation Symptom Assessment (ACSA) Total Score14.3 ± 10.59
SecondaryPatient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)

The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered the following questions: 1. Were you hospitalized in the past month, 2. Do you work for pay, 3. If you missed time at work last week, please note all the reasons why, 4. Would you say that the past week was typical, like the rest of the 3 weeks this month, in terms of your working hours, 5. Do you do volunteer work (VW), and 6. If you do not receive money for your work and do not participate in volunteer work, the reason is. Number of participants with response is reported.

Time frame:
Week 52/ET
Reported as:
Number · participants
Patient Resource Utilization Questionnaire - Major Depressive Disorder (PRUQ-MDD)
participantsSPD489 + Antidepressant
Hospitalized in Past Month4
Work for Pay337
Reason Missing Work Time: Had a Day Off24
Reason Missing Work Time: Physically Ill10
Reason Missing Work Time: Upset/Depressed/Nervous15
Reason Missing Work Time: Other36
Past Week Was Typical: Yes249
Past Week Was Typical: No, Worked More Hours43
Past Week Was Typical: No, Worked Less Hours45
Volunteer Work86
Reason no Money/VW: Physically Ill6
Reason no Money/VW: Upset/Depressed/Nervous30
Reason no Money/VW: Cannot Find Work39
Reason no Money/VW: Other48
Reason no Money/VW: Not Applicable348
SecondaryPRUQ-MDD - Number of Days of Resource Utilization

The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Number of nights in medical/surgical ward, number of nights in ICU, and number of days a participant received home care in the past month are reported.

Time frame:
Week 52/ET
Reported as:
Mean · days
PRUQ-MDD - Number of Days of Resource Utilization
daysSPD489 + Antidepressant
Number of nights in medical/surgical ward (n=4)1.3 ± 0.50
Number of nights in ICU (n=4)0.0 ± 0.00
Number of days received home care in past month0.0 ± 0.00
SecondaryPRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)

The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many times did you visit the following healthcare providers in the past month: Family doctor/primary care, Non-physician healthcare practitioner (NPHP), Psychiatrist/Psychologist/Counselor (PPC); 2. How many times did you take one of the tests, mentioned below, during the past month: Blood test, CT Scan, X Ray, Renal function, Thyroid function; and 3. How many times did you visit the hospital emergency room (ER), urgent care facility (UCF) or an after-hours clinic (AHC) in the past month. Number of events (visit to health care provider, visit to hospital facilities, and number of times a test was performed) are reported.

Time frame:
Week 52/ET
Reported as:
Mean · events
PRUQ-MDD - Number of Events (Visit to Health Care Provider/Visit to Hospital Facilities/Number of Times a Test Was Performed)
eventsSPD489 + Antidepressant
Visit to Family doctor/primary care (n=481)0.2 ± 0.58
Visit to NPHP(n=480)0.1 ± 0.43
Visit to PPC(n=481)0.1 ± 0.86
Test performed: Blood Test (n=480)0.2 ± 2.30
Test performed: CT Scan (n=480)0.0 ± 0.08
Test performed: X Ray (n=480)0.0 ± 0.20
Test performed: Renal function (n=480)0.0 ± 0.00
Test performed: Thyroid function (n=480)0.0 ± 0.09
Test performed: Other test (n=479)0.1 ± 0.49
Visit to Hospital ER, UCF or AHC (n=482)0.0 ± 0.23
SecondaryPRUQ-MDD - Number of Hours

The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions - 1. How many hours do you usually work or would you usually be expected to work (hrs/week); 2. How many hours did you actually work last week; 3. On average, how many hours do you volunteer per week. Number of hours are reported.

Time frame:
Week 52/ET
Reported as:
Mean · hours
PRUQ-MDD - Number of Hours
hoursSPD489 + Antidepressant
Work or usually expect to work (n=337)34.0 ± 11.85
Actual work (n=337)31.2 ± 15.13
Average volunteer per week (n=86)8.6 ± 8.94
SecondaryPRUQ-MDD - Effect of Depressive Symptoms

The PRUQ-MDD assessed the long term economic outcomes. It collects utilization of healthcare resources reported by the study participants. Participants answered following questions on a 0 to 10 point scale - 1. During past week, how much did depressive symptoms affect work productivity; 2. During past week, how much did depressive symptoms affect regular non-work daily activities. Higher scores indicates more effect of depressive symptoms on work productivity and non-work daily activities.

Time frame:
Week 52/ET
Reported as:
Mean · units on scale
PRUQ-MDD - Effect of Depressive Symptoms
units on scaleSPD489 + Antidepressant
Affected work productivity (n= 335)2.1 ± 2.37
Affected regular non work daily activities (n=482)2.5 ± 2.43

Adverse events

Collected over Up to Week 53. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489 + Antidepressant—33/1,559 (2.1%)921/1,559 (59.1%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventSPD489 + Antidepressant
Suicidal ideationPsychiatric disorders3/1559
Suicide attemptPsychiatric disorders3/1559
Non-Cardiac chest painGeneral disorders2/1559
DepressionPsychiatric disorders2/1559
Deep vein thrombosisVascular disorders2/1559
Angina pectorisCardiac disorders1/1559
Abdominal painGastrointestinal disorders1/1559
Intestinal strangulationGastrointestinal disorders1/1559
Small intestinal obstructionGastrointestinal disorders1/1559
Chest painGeneral disorders1/1559
Most frequent other events
Showing 10 of 13
Most frequent other events
EventSPD489 + Antidepressant
HeadacheNervous system disorders241/1559
Dry mouthGastrointestinal disorders212/1559
InsomniaPsychiatric disorders204/1559
Decreased appetiteMetabolism and nutrition disorders189/1559
NasopharyngitisInfections and infestations137/1559
NauseaGastrointestinal disorders116/1559
Upper respiratory tract infectionInfections and infestations100/1559
DizzinessNervous system disorders91/1559
BruxismPsychiatric disorders89/1559
AnxietyPsychiatric disorders83/1559

Baseline characteristics

Safety analysis set included all participants who took at least 1 dose of investigational product and had at least 1 post-Visit 0 (Week 0) safety assessment in this study.

Age, Continuous
Age, Continuous(years)SPD489 + Antidepressant
Mean41.9 ± 11.89
Age, Customized
Age, Customized(Participants)SPD489 + Antidepressant
18-55 Years1333
56-65 Years226
Sex: Female, Male
Sex: Female, Male(Participants)SPD489 + Antidepressant
Female1056
Male503
Region of Enrollment
Region of Enrollment(Participants)SPD489 + Antidepressant
United States1190
Estonia24
Hungary4
Czech Republic83
Mexico27
Canada36
Finland8
Spain6
Poland20
Romania8
South Africa5
Chile33
Germany69
Argentina27
Australia13
United Kingdom1
Croatia5
08

Study locations

212 sites
  • Birmingham Research Group
    Birmingham, Alabama 35216, United States
  • ResearchOne, Inc.
    Scottsdale, Arizona 85251, United States
  • Arkansas Psychiatric Clinical Research Trials, P.A.
    Little Rock, Arkansas 72223, United States
  • South Coast Clinical Trials, Inc.
    Anaheim, California 92804, United States
  • American Neuropsychiatric Research, Inc.
    Carson, California 90746, United States
  • Catalina Research Institute, LLC
    Chino, California 91710, United States
  • Shanti Clinical Trials
    Colton, California 92324, United States
  • ATP Clinical Research
    Costa Mesa, California 92626, United States
  • Clinical Innovation, Inc.
    Costa Mesa, California 92626, United States
  • Diligent Clinical Trials
    Downey, California 90241, United States
  • Synergy Clinical Research Center of Escondido
    Escondido, California 92025, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • UC, Irvine Child Development Center
    Irvine, California 92612, United States
  • Irvine Center For Clinical Research
    Irvine, California 92618, United States
  • Omega Clinical Trials, LLC
    La Habra, California 90631, United States
  • Semel Institute for Neuroscience & Human Behavior at UCLA
    Los Angeles, California 90024, United States
  • Pacific Research Partners
    Oakland, California 94612, United States
  • North County Clinical Research
    Oceanside, California 92066, United States
  • Pasadena Research Institute, LLC
    Pasadena, California 91106, United States
  • Anderson Clinical Research
    Redlands, California 92374, United States
  • BreakThrough Clinical Trials, LLC
    San Bernardino, California 92408, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • PCSD - Feighner Research
    San Diego, California 92108, United States
  • Clinical Innovations, Inc.
    San Diego, California 92121, United States
  • Sharp Mesa Vista Hospital
    San Diego, California 92123', United States
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Neuropsychiatric Center of Orange County
    Santa Ana, California 92701, United States
  • Caliifornia Neuroscience Research Medical Group
    Sherman Oaks, California 91403, United States
  • MCB Clinical Research Centers
    Colorado Springs, Colorado 80910, United States
  • Western Affiliated Research Institute
    Denver, Colorado 80209, United States
  • Connecticut Clinical Research
    Cromwell, Connecticut 06416, United States
  • Geriatric and Adult Psychiatry, LLC
    Hamden, Connecticut 06518, United States
  • Institute of Living - Hartford Hospital
    Hartford, Connecticut 06106, United States
  • The Hospital of Central Connecticut
    New Britain, Connecticut 06050, United States
  • Florida Clinical Research Center, LLC
    Bradenton, Florida 34201, United States
  • CNS Clinical Research Group
    Coral Springs, Florida 33067, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Emerald Coast Mood & Memory, PA
    Fort Walton Beach, Florida 32547, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32216, United States
  • Amit Vijapura MD
    Jacksonville, Florida 32256, United States
  • Psychiatric Associates
    Lake City, Florida 32025, United States
  • Florida Clinical Research Center, LLC
    Maitland, Florida 32751, United States
  • Suncoast Clinical Research
    New Port Richey, Florida 34652, United States
  • Fidelity Clinical Research Inc
    North Miami, Florida 33161, United States
  • Scientific Clinical Research Inc.
    North Miami, Florida 33161, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32806, United States
  • Compass Research, LLC
    Orlando, Florida 32806, United States
  • Ali A. Kashfi, MD, PA
    Orlando, Florida 32889, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Comprehensive Clinical Development, Inc.
    Saint Petersburg, Florida 33716, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Kolin Research Group
    Winter Park, Florida 32789, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Atlanta Institute of Medicine & Research
    Atlanta, Georgia 30328, United States
  • Carman Research
    Smyrna, Georgia 30080, United States
  • Institute for Behavioral Medicine, LLC
    Smyrna, Georgia 30080, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Alexian Brothers Center for Psychiatric Research
    Hoffman Estates, Illinois 60169, United States
  • American Medical Research, Inc.
    Oakbrook Terrace, Illinois 60523, United States
  • Psyichiatric Medicine Associates, LLC
    Skokie, Illinois 60076, United States
  • Sleep and Behavior Medicine Institute
    Vernon Hills, Illinois 60061, United States
  • Davis Clinic
    Indianapolis, Indiana 46250, United States
  • Pedia Research, LLC
    Newburgh, Indiana 47630, United States
  • Northwest Indiana Center for Clinical Research
    Valparaiso, Indiana 46383, United States
  • Clinical Trials Technology, Inc.
    Prairie Village, Kansas 66206, United States
  • Heartland Research Associates
    Wichita, Kansas 67207, United States
  • MCM Clinical Research LLC
    Florence, Kentucky 41042, United States
  • Pedia Research, LLC
    Owensboro, Kentucky 42301, United States
  • Louisiana Clinical Research LLC
    Shreveport, Louisiana 71101, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • Potomac Grove Clinical Research Center
    Gaithersburg, Maryland 20877, United States
  • Office of Marc Hertzman, MD
    Rockville, Maryland 20852, United States
  • Adams Clinical Trials, LLC
    Watertown, Massachusetts 02472, United States
  • Comprehensive Psyichatric Associates
    Gladstone, Missouri 64118, United States
  • The Center for Pharmaceutical Research PC
    Kansas City, Missouri 64114, United States
  • Private Practice - Howard J. Ilivicky
    O'Fallon, Missouri 63368, United States
  • St. Charles Psychiatric Associates - Midwest Research Group
    Saint Charles, Missouri 63301, United States
  • Mid-America Clinical Research
    Saint Louis, Missouri 63109, United States
  • Mercy Health Research
    Saint Louis, Missouri 63141, United States
  • Premier Psychiatric Research Institute
    Lincoln, Nebraska 68526, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • Center For Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • CRI Worldwide, LLC
    Willingboro, New Jersey 08046, United States
  • Albuquerque Neuroscience Inc.
    Albuquerque, New Mexico 87109, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Brooklyn Medical Institutes
    Brooklyn, New York 11214, United States
  • Comprehensive Clinical Development, Inc.
    Fresh Meadows, New York 11366, United States
  • Bioscience Research LLC
    Mount Kisco, New York 10549, United States
  • Clinilabs, Inc.
    New York, New York 10019, United States
  • Medical & Behavioral Health Research, PC
    New York, New York 10023, United States
  • Fieve Clinical Research
    New York, New York 10075, United States
  • Mount Sinai School of Medicine
    New York, New York 11029, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Sleep Medicine Centers of Western New York
    West Seneca, New York 14224, United States
  • Triangle Neuropsyhiatry
    Durham, North Carolina 27707, United States
  • Clinical Trials of America
    Hickory, North Carolina 28601, United States

Showing the first 100 of 212 sites across 14 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2012 to primary completion in Mar 2014, 25 months.

Results were first posted in Feb 2015, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2011
First posted
Sep 19, 2011
StartActual
Feb 27, 2012
Primary completionActual
Mar 27, 2014
CompletionActual
Mar 27, 2014
Results first posted
Feb 23, 2015
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01436175
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Sep 19, 2011
Start date
Feb 27, 2012
Primary completion
Mar 27, 2014
Completion
Mar 27, 2014
Results posted
Feb 23, 2015
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion